<?xml version="1.0" encoding="UTF-8"?>
<p>Hepatic artery infusion (HAI) chemotherapy provides high drug exposure of the tumor at first passage, which offers theoretical advantages over systemic administration of drugs (
 <xref rid="B7" ref-type="bibr">7</xref>, 
 <xref rid="B8" ref-type="bibr">8</xref>). Floxuridine (FUDR), a deoxyribonucleoside derivative of 5-Fu, is an ideal agent for HAI due to its short half-life and extensive first pass extraction (
 <xref rid="B9" ref-type="bibr">9</xref>). Commonly, FUDR was administered continuously at low dose 
 <italic>via</italic> HAI pump in combination with standard systemic chemotherapy (SCT). We and others have demonstrated that HAI plus SCT is effective in improving hepatic response and prolonging survival in colorectal cancer liver metastases (CRCLM) (
 <xref rid="B10" ref-type="bibr">10</xref>–
 <xref rid="B13" ref-type="bibr">13</xref>). Recently, HAI FUDR was also demonstrated to be effective in intrahepatic cholangiocarcinoma (IHC) (
 <xref rid="B14" ref-type="bibr">14</xref>).
</p>
